Veradermics (NYSE:MANE – Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.58) EPS for the quarter, hitting the consensus estimate of ($0.58), FiscalAI reports.
Veradermics Trading Up 1.9%
Shares of Veradermics stock traded up $2.03 during trading on Thursday, reaching $111.08. 217,593 shares of the stock were exchanged, compared to its average volume of 598,981. The stock’s fifty day moving average is $109.26. The firm has a market cap of $4.64 billion and a price-to-earnings ratio of -83.68. Veradermics has a 1 year low of $32.00 and a 1 year high of $131.24.
Wall Street Analyst Weigh In
Several research firms have weighed in on MANE. Needham & Company LLC boosted their price target on shares of Veradermics from $136.00 to $164.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. UBS Group set a $170.00 target price on Veradermics in a research note on Wednesday, July 15th. Citigroup increased their target price on Veradermics from $135.00 to $160.00 and gave the company a “buy” rating in a report on Thursday, July 16th. Weiss Ratings assumed coverage on Veradermics in a research note on Tuesday, May 26th. They issued a “sell (d+)” rating on the stock. Finally, B. Riley Financial initiated coverage on Veradermics in a research report on Wednesday, July 15th. They issued a “buy” rating and a $170.00 price objective for the company. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Veradermics has a consensus rating of “Moderate Buy” and a consensus target price of $153.00.
Veradermics Company Profile
We are a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Our initial focus is developing better treatments for pattern hair loss, or PHL, a condition affecting approximately 50 million men and 30 million women in the United States. Current PHL treatment options are limited and therefore are consistently plagued with high rates of treatment failure, patient dissatisfaction and treatment discontinuation.
Recommended Stories
- Five stocks we like better than Veradermics
- Lumentum Just Delivered the AI Growth Investors Wanted
- Ryman Checks Into a $1.38B Hospitality Upgrade
- Axos Financial Keeps Proving the Digital Banking Model Works
- SpaceX’s First Earnings Report Only Made Wall Street More Divided
Receive News & Ratings for Veradermics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veradermics and related companies with MarketBeat.com's FREE daily email newsletter.
